Skip to main content
. 2020 Jan 29;10:1637. doi: 10.3389/fphar.2019.01637

Table 1.

Study characteristics.

Study Number of centers Definition of ARDS Sample size Location Sedation strategy NMBA usage
Gainnier, 2004 4 PaO2:FIO2 ratio <150 mmHg and PEEP ≥5cmH2O 56 France Midazolam and sufentanil A bolus of 50 mg cisatracurium, followed by 5 μg/(kg∙min) infusion for 48 h.
Forel, 2006 3 PaO2:FIO2 ratio <200 mmHg and PEEP ≥5cmH2O 36 France Midazolam and sufentanil A bolus of 0.2 mg/kg cisatracurium, followed by 5 μg/(kg∙min) infusion for 48 h.
Papazian, 2010 20 PaO2:FIO2 ratio < 150 mmHg and PEEP ≥5cmH2O 339 France Midazolam, sufentanil, Ketamin and propofol A bolus of 15 mg cisatracurium followed by 37.5 mg per hour for 48 hours.
Guervilly, 2017 2 PaO2:FIO2 ratio <150 mmHg and PEEP ≥5cmH2O 24 France Midazolam and sufentanil A bolus of 15 mg cisatracurium, followed 37.5 mg per hour for 48 hours.
Moss, 2019 13 PaO2:FIO2 ratio <150 mmHg and PEEP ≥8cmH2O 1006 America Not mandate A bolus of 15 mg cisatracurium, followed 37.5 mg per hour for 48 hours.

NMBA, neuromuscular blocking agents; ARDS, acute respiratory distress syndrome; PEEP, positive end-expiratory pressure; ICU, intensive care unit.